Gensaic

Gensaic combines AI-powered protein design with unbiased directed evolution to develop tissue-selective ligands for targeted intracellular therapeutic delivery. The company's portfolio advances therapies for metabolic and age-related diseases, with an initial focus on siRNA payloads. FORGE™, Gensaic's proprietary product engine, integrates phage display for unbiased protein evolution within a generative AI architecture to discover and optimize protein molecules with enhanced tissue selectivity and drug-like properties. Founded through MIT and based in Cambridge, Massachusetts, Gensaic's team of physicians, bioengineers, and machine learning scientists is advancing a singular objective: to enable selective delivery of any therapeutic payload to any tissue of interest. For more information, please visit gensaic.com.